These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14713821)

  • 1. Botulinum toxin type B for type A resistant bladder spasticity.
    Pistolesi D; Selli C; Rossi B; Stampacchia G
    J Urol; 2004 Feb; 171(2 Pt 1):802-3. PubMed ID: 14713821
    [No Abstract]   [Full Text] [Related]  

  • 2. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity.
    Reitz A; Schurch B
    J Urol; 2004 Feb; 171(2 Pt 1):804; discussion 804-5. PubMed ID: 14713822
    [No Abstract]   [Full Text] [Related]  

  • 3. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
    Pistolesi D; Giannarini G; Stampacchia G; Selli C
    Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with botulinum toxin in neurologic pediatrics].
    Justus N; Lee SH; Berweck S; Heinen F
    Kinderkrankenschwester; 2007 Jul; 26(7):274-6. PubMed ID: 17726921
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report.
    Dykstra DD; Pryor J; Goldish G
    Arch Phys Med Rehabil; 2003 Sep; 84(9):1399-400. PubMed ID: 13680581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin. From poison to medical wonder.
    Mayo Clin Health Lett; 2006 Dec; 24(12):4-5. PubMed ID: 17310508
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of botulinum toxin for genitourinary conditions: What is the evidence?
    da Silva CM; Chancellor MB; Smith CP; Cruz F
    Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical electromotive botulinum toxin type A administration for management of concomitant neuropathic bowel and bladder dysfunction in children.
    Kajbafzadeh AM; Sharifi-Rad L; Ladi-Seyedian SS
    Int J Colorectal Dis; 2016 Jul; 31(7):1397-9. PubMed ID: 26847618
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of overactive bladder with botulinum toxin type B: a pilot study.
    Dykstra D; Enriquez A; Valley M
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Dec; 14(6):424-6. PubMed ID: 14677005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum A toxin in spinal cord injury.
    Schurch B
    Arch Phys Med Rehabil; 1998 Nov; 79(11):1481. PubMed ID: 9821915
    [No Abstract]   [Full Text] [Related]  

  • 12. Study of botulinum toxin A in neurogenic bladder due to spina bifida in children.
    Deshpande AV; Sampang R; Smith GH
    ANZ J Surg; 2010 Apr; 80(4):250-3. PubMed ID: 20575951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin-A therapy in pediatric urology: indications for the neurogenic and non-neurogenic neurogenic bladder.
    Dyer LL; Franco I
    ScientificWorldJournal; 2009 Nov; 9():1300-5. PubMed ID: 19936566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum-A toxin in the treatment of neurogenic bladder in children.
    Schulte-Baukloh H; Knispel HH; Michael T
    Pediatrics; 2002 Aug; 110(2 Pt 1):420-1. PubMed ID: 12165609
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections.
    Pascali MP; Mosiello G; Boldrini R; Salsano ML; Castelli E; De Gennaro M
    J Urol; 2011 Jun; 185(6 Suppl):2552-7. PubMed ID: 21527192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events after botulinum A toxin injection for neurogenic voiding disorders.
    De Laet K; Wyndaele JJ
    Spinal Cord; 2005 Jul; 43(7):397-9. PubMed ID: 15741978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.
    Corcos J; Biardeau X; Aharony S
    World J Urol; 2015 Jun; 33(6):899-901. PubMed ID: 26217823
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
    Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.